Headlands Technologies LLC Has $119,000 Stock Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Headlands Technologies LLC grew its holdings in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREFree Report) by 50.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,351 shares of the biopharmaceutical company’s stock after purchasing an additional 1,127 shares during the quarter. Headlands Technologies LLC’s holdings in Ultragenyx Pharmaceutical were worth $119,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in RARE. Signaturefd LLC boosted its position in Ultragenyx Pharmaceutical by 42.6% during the second quarter. Signaturefd LLC now owns 1,021 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 305 shares during the period. Van ECK Associates Corp bought a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $53,000. American International Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 36.3% in the second quarter. American International Group Inc. now owns 1,257 shares of the biopharmaceutical company’s stock valued at $58,000 after acquiring an additional 335 shares during the period. Lazard Asset Management LLC boosted its position in shares of Ultragenyx Pharmaceutical by 36.6% in the first quarter. Lazard Asset Management LLC now owns 896 shares of the biopharmaceutical company’s stock valued at $64,000 after acquiring an additional 240 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Ultragenyx Pharmaceutical by 97.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $65,000 after acquiring an additional 903 shares during the period. Institutional investors own 96.37% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on RARE shares. Morgan Stanley cut their price objective on shares of Ultragenyx Pharmaceutical from $90.00 to $84.00 and set an “overweight” rating for the company in a research report on Friday, November 3rd. Piper Sandler cut their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $130.00 and set an “overweight” rating for the company in a research report on Wednesday, October 25th. Robert W. Baird raised their price objective on shares of Ultragenyx Pharmaceutical from $57.00 to $68.00 and gave the company an “outperform” rating in a research report on Tuesday, January 30th. Wells Fargo & Company assumed coverage on shares of Ultragenyx Pharmaceutical in a research note on Friday, December 8th. They issued an “overweight” rating and a $72.00 target price on the stock. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $114.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Friday, January 19th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $90.60.

View Our Latest Report on Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Stock Up 2.8 %

Shares of RARE opened at $46.73 on Monday. The firm’s 50 day simple moving average is $45.38 and its 200 day simple moving average is $40.03. Ultragenyx Pharmaceutical Inc. has a 1-year low of $31.52 and a 1-year high of $54.98.

Ultragenyx Pharmaceutical Company Profile

(Free Report)

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

Featured Articles

Want to see what other hedge funds are holding RARE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREFree Report).

Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.